Search This Blog

Thursday, October 1, 2026

Teva, Samsung Bioepis in global license, development, commercialization pact for up to 6 biosimilars

 

Teva, Samsung Bioepis sign global license, development and commercialization pact for up to six biosimilars, including Fasenra and Ilaris

  • Agreement grants Teva rights to commercialize the biosimilar candidates in the U.S., Europe and Canada.
  • Teva also receives options for additional commercialization territories beyond the U.S., Europe and Canada.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)